COMMUNIQUÉS West-GlobeNewswire

-
Cytek Biosciences Announces $50 Million Stock Repurchase Program
06/06/2024 -
electroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
06/06/2024 -
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
06/06/2024 -
OneMedNet Significantly Expands Industry Access to Proprietary iRWD™ Network and Platform by Joining AWS Partner Network
06/06/2024 -
Breckenridge Distillery Wins Double Gold for a Consecutive Year in a Row at the 2024 New York International Spirits Competition
06/06/2024 -
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
06/06/2024 -
Venus Concept Regains Compliance with Nasdaq’s Minimum Equity Requirement
06/06/2024 -
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
06/06/2024 -
Virbac : Declaration of the number of shares and voting rights 05/2024
06/06/2024 -
Virbac : Déclaration d'actions et de droits de vote 05/2024
06/06/2024 -
Cartesian Therapeutics Announces New Employment Inducement Grant
06/06/2024 -
Redecan Cannabis Introduces New Top Shelf Flower 'Purple Churro'
06/06/2024 -
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
06/06/2024 -
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
06/06/2024 -
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
06/06/2024 -
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
06/06/2024 -
PetVivo Appoints Former NOVUS and Colgate-Palmolive Senior Sales & Marketing Executive, Bryan Monninger, as VP of Sales
06/06/2024 -
Castellum, Inc. Continues to Reduce Debt
06/06/2024 -
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
06/06/2024
Pages